Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Marc S. Sabatine; Robert P. Giugliano; Anthony Keech; Narimon Honarpour; Huei Wang; Thomas Liu; Scott M. Wasserman; Robert C. Scott; Peter Sever; Terje R. Pedersen

doi:10.1016/j.ahj.2015.11.015

Keywords

MedicinePCSK9Research designInternal medicineRandomized controlled trialCholesterolIntensive care medicineLDL receptor

Affiliated Institutions

Related Publications

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Scott M. Grundy , James I. Cleeman , C. Noel Bairey Merz +6 more

The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the pub...

2004 Circulation 6899 citations

Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Curt D. Furberg , Jackson T. Wright , Barry R. Davis +7 more

Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately e...

2002 JAMA 1323 citations

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

Paul M. Ridker

Twenty-two years ago, the landmark 4S trial demonstrated that statin therapy could reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among second...

2016 European Heart Journal 255 citations

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

Peter H. Jones , John A. Farmer , Michael D. Cressman +12 more

Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...

1991 Clinical Cardiology 65 citations

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

John R. Guyton , David M. Herrington , Mary P. McGowan +3 more

The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or ...

2004 The American Journal of Cardiology 198 citations

Publication Info

Year: 2015
Type: article
Volume: 173
Pages: 94-101
Citations: 171
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

171

OpenAlex

Cite This

APA Style

                            
                                    Marc S. Sabatine, 
                                
                                    Robert P. Giugliano, 
                                
                                    Anthony Keech
                                
                                et al.
                            
                            (2015). 
                            Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. 
                            American Heart Journal
                            , 173
                            
                            , 94-101.
                            https://doi.org/10.1016/j.ahj.2015.11.015

Identifiers

DOI: 10.1016/j.ahj.2015.11.015